Physician profile
Thomas Herbert Koerner
NPI 1316942550
$2,007.88
in general payments reported to CMS, 2019-2025
21 companies · $300 in 2025
The $300 reported for 2025 was more than what 85% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $78.60 · 2021: $667 · 2022: $261 · 2023: $253 · 2024: $242 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $650.85 | 2019-2025 | Bexsero, Penmenvy, Pediarix |
| Merck Sharp & Dohme LLC | $203.65 | 2019-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Cranial Technologies, INC | $149.75 | 2019-2025 | Doc Band |
| Corium, LLC | $135.94 | 2022-2025 | Azstarys |
| Cumberland Pharmaceuticals, INC. | $135.41 | 2022-2023 | Kristalose |
| Pfizer INC. | $120.32 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.14 | 2019-2022 | |
| Seqirus USA INC | $86.83 | 2023-2025 | Flucelvax Quadrivalent, Flucelvax |
| Ironshore Pharmaceuticals INC. | $76.39 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $61.43 | 2022-2025 | Flumist Quadrivalent |
| Collegium Pharmaceutical, INC. | $40.56 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $39.91 | 2024 | |
| Kaleo, INC. | $36.40 | 2021 | |
| Neos Therapeutics, LP | $32.84 | 2019 | |
| Sobi, INC | $29.86 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $28.55 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $21.94 | 2024 | Crysvita |
| Shire North American Group INC | $21.81 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $16.23 | 2025 | Neffy |
| Phadia US INC. | $14.91 | 2025 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $13.16 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Koerner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.